ANN ARBOR—Terumo Cardiovascular, a cardiovascular surgery products provider, announced a collaboration with Monmouth Junction, N.J.-based CytoSorbents Corp., to sell the latter company’s product CytoSorb to hospitals in 10 COVID-19 hotspot states.

The states are Alabama, Arizona, California, Georgia, Louisiana, Mississippi, New Mexico, Oregon, Texas, and Washington.

The product is designed to treat cytokine storm, a dangerous complication in severe COVID-19 cases that causes severe inflammation and organ failure. CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically ill COVID-19 patients with imminent or confirmed respiratory failure.

Under the initial terms of the agreement, Terumo Cardiovascular will ensure hospitals in the defined hot-spot states have access to the CytoSorb therapy for use in critically ill COVID-19 patients that meet strict criteria under CytoSorbents’ EUA. CytoSorbents will provide all primary clinical and technical training, customer support, and product fulfillment.

For more information, click on